Site updated at Wednesday, 22 June 2016

Living with Dementia


Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment

Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid™, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer’s Disease and other causes… Eli Lilly Announces FDA Approval of Amyvid For Alzheimer’s Assessment   

FDA OKs Agent to Differentiate Alzheimer’s

The FDA has approved the radioactive diagnostic agent florbetapir (Amyvid) for evaluation of the causes of cognitive decline, including Alzheimer’s disease, according to Eli Lilly, developer of the compound.

Florbetapir is used in conjunction with positron emission tomography to evaluate the burden of amyloid plaques in the brain, according to Daniel Skovronsky, MD, PhD,… FDA OKs Agent to Differentiate Alzheimer’s   


frontal-lobe degeneration1 - mildcognitive impairment1 - alzheimer's disease195 - overweight people1 - sign of alzheimer's1 - alzheimer's diagnosis2 - mediterranean diet1 - resveratrol1 - gammagard1 - dysarthria1 - dementia decline1 - amyloid-β1 - risk for dementia1 - alzheimers patients3 - dementia care4 - computerized tomography1 - poor judgment2 - senility1 - age-related cognitive disorders1 - leg tremors1 - behaviours redolent1 - fight dementia1 - transcatheter aortic valve implantation2 - protein alpha-synuclein1 - guv membrane1 - baroness thatcher1 - olanzapine1 - korsakoff psychosis11 - wernicke syndrome1 - short-term memory problems1 -